Table 4

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries

Ekaterina V. Kurbatova

, Tracy Dalton, Julia Ershova, Thelma E. Tupasi, Janice Campos Caoili, Martie L. van der Walt, Charlotte L. Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, HeeJin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, and J. Peter Cegielski

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, T. Dalton, J. Ershova, J. Campos Caoili, C. Kvasnovsky, J.P. Cegielski); Tropical Disease Foundation, Manila, the Philippines (T. Tupasi, J. Campos Caoili); Medical Research Council, Pretoria, South Africa (M. Van Der Walt, C. Kvasnovsky); National Institute of Health, Lima, Peru (M. Yagui); Socios en Salud Sucursal Perú, Lima (J. Bayona, C. Contreras); Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia (V. Leimane); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA (L.E. Via); University of Cape Town, Cape Town, South Africa (L.E. Via):; Korean Institute of TB, Seoul, South Korea (H. Kim); Ministry of Public Health, Bangkok, Thailand (S. Akksilp); Orel Oblast Tuberculosis Dispensary, Orel, Russia (B.Y. Kazennyy); Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russia (G.V. Volchenkov); Taiwan Centers for Disease Control, Taipei, Taiwan (R. Jou); Tartu University Hospital, Tartu, Estonia (K. Kliiman); Russian Academy of Medical Sciences, Moscow, Russia (O.V. Demikhova)

Main Article

Association of patient characteristics with candidacy for a short (9-month) regimen or a BDQ-containing regimen among patients with MDR TB*

Characteristic	Patient candidate, no. (%)			p value
Characteristic	Total	Short regimen	BDQ-containing regimen	p value
Sex
M	804	613 (76.2)	191 (23.8)	0.72
F	450	339 (75.3)	111 (24.7)
Employment status
Unemployed	475	328 (69.1)	147 (30.9)	<0.001
Disabled, retired, student, housewife	192	150 (78.1)	42 (21.9)	0.37
Employed	581	471 (81.1)	110 (18.9)
History of imprisonment
Yes	81	50 (61.7)	31 (38.3)	0.001
Unknown	181	130 (71.8)	51 (28.2)	0.08
No	992	772 (77.8)	220 (22.2)
Homeless
Yes	29	21 (72.4)	8 (27.6)	0.54
Unknown	137	91 (66.4)	46 (33.6)	0.005
No	1,088	840 (77.2)	248 (22.8)
Alcohol abuse
Yes	186	108 (58.1)	78 (41.9)	<0.001
Unknown	52	31 (59.6)	21 (40.4)	<0.001
No	1,016	813 (80)	203 (20)
HIV status
Positive	159	108 (67.9)	51 (32.1)	0.88
Unknown	468	422 (90.2)	46 (9.8)	<0.001
Negative	627	422 (67.3)	205 (32.7)
Any co-morbidity other than HIV infection
Yes	335	257 (76.7)	78 (23.3)	0.69
No	919	695 (75.6)	224 (24.4)
Classification by prior treatment history
Received first-line drugs	879	719 (81.8)	160 (18.2)	<0.001
Received second-line injectable drugs	185	103 (55.7)	82 (44.3)	0.04
New case	168	112 (66.7)	56 (33.3)
Classification by prior TB treatment outcome
Relapse	181	124 (68.5)	57 (31.5)	0.66
Failure, loss to follow up, change to second-line regimen	598	444 (74.2)	154 (25.8)	0.04
Chronic	190	172 (90.5)	18 (9.5)	<0.001
Unknown	119	102 (85.7)	17 (14.3)	<0.001
New case	166	110 (66.3)	56 (33.7)
Body mass index
<18.5	471	369 (78.3)	102 (21.7)	0.12
>18.5	783	583 (74.5)	200 (25.5)
Site of TB disease
Extrapulmonary and pulmonary	57	45 (78.9)	12 (21.1)	0.59
Pulmonary only	1,195	906 (75.8)	289 (24.2)
Bilateral TB disease
Yes	993	748 (75.3)	245 (24.7)	0.48
No	236	183 (77.5)	53 (22.5)
Cavities on chest radiograph
Unilateral	477	339 (71.1)	138 (28.9)	<0.001
Bilateral	293	210 (71.7)	83 (28.3)	<0.001
No	484	403 (83.3)	81 (16.7)
AFB smear at the start of MDR treatment
Positive	1,063	810 (76.2)	253 (23.8)	0.37
Negative	155	113 (72.9)	42 (27.1)

*Row percentages show proportion of patients with each characteristic that would be candidates for a particular regimen. AFB, acid-fast bacilli; BDQ, bedaquiline; MDR, multidrug-resistant; TB, tuberculosis.Bold type indicates statistical significance.

Main Article

Page created: May 15, 2015

Page updated: May 15, 2015

Page reviewed: May 15, 2015

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.